Evidence map›Paper›PMID 32828825›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2020

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

J K Litton, S A Hurvitz, L A Mina, H S Rugo, K-H Lee, A Gonçalves, S Diab, N Woodward, A Goodwin, R Yerushalmi and 10 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
250citing papers in PubMed, 12 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

250 citing papers in PubMed, 12 syntheses or guidelines pooled it, 376 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

190 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 8 countries.

J K LittonThe University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jlitton@mdanderson.org.
S A HurvitzUniversity of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA.
L A MinaBanner M.D. Anderson Cancer Center, Gilbert, USA.
H S RugoUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
K-H LeeSeoul National University Hospital, Seoul, South Korea.
A GonçalvesInstitut Paoli-Calmettes, Marseille, France.
S DiabRocky Mountain Cancer Centers, Littleton, USA.
N WoodwardMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Australia.
A GoodwinMedical Oncology Department, Concord Repatriation General Hospital, Concord, Australia.
R YerushalmiRabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
H RochéInstitut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Y-H ImSamsung Medical Center, Seoul, South Korea.
W EiermannInterdisziplinäres Onkologisches Zentrum München, Munich, Germany.
R G W QuekPfizer Inc., San Francisco, USA.
T UsariPfizer Oncology, Milan, Italy.
S LanzalonePfizer Oncology, Milan, Italy.
A CziberePfizer Inc., Cambridge, USA.
J L BlumTexas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, USA.
M MartinInstituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain.
J EttlDepartment of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Pfizer (Italy) · ITPfizer (United States) · USThe University of Texas MD Anderson Cancer Center · USConcord Repatriation General Hospital · AUHospital General Universitario Gregorio Marañón · ESInstitut Claudius Regaud · FRInstitut Paoli-Calmettes · FRMater Research · AURabin Medical Center · ILRocky Mountain Cancer Centers · USSamsung Medical Center · KRSeoul National University Hospital · KRTechnical University of Munich · DEThe US Oncology Network · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundIn EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall survival (OS). PATIENTS AND

methodsThis randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician's choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments.

resultsA total of 431 patients were entered in a randomized study (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By 30 September 2019, 216 deaths (75.3%) occurred for talazoparib and 108 (75.0%) chemotherapy; median follow-up was 44.9 and 36.8 months, respectively. HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670-1.073; P = 0.17); median (95% CI) 19.3 months (16.6-22.5 months) versus 19.5 months (17.4-22.4 months). Kaplan-Meier survival percentages (95% CI) for talazoparib versus chemotherapy: month 12, 71% (66% to 76%)/74% (66% to 81%); month 24, 42% (36% to 47%)/38% (30% to 47%); month 36, 27% (22% to 33%)/21% (14% to 29%). Most patients received subsequent treatments: for talazoparib and chemotherapy, 46.3%/41.7% received platinum and 4.5%/32.6% received a poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503-1.029). Grade 3-4 adverse events occurred in 69.6% (talazoparib) and 64.3% (chemotherapy) patients, consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favoring talazoparib versus chemotherapy (P < 0.01 for all), consistent with initial analyses.

conclusionsIn gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.

Indexed as

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinGerm CellsGerm-Line MutationHumansPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsQuality of LifeBRCA1 ProteinBRCA1 protein, humanPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparibbreast cancergermline BRCA mutationoverall survivalPARP inhibitortalazoparib

Identifiers

PMID32828825
PMCPMC10649377
OpenAlexW3069915980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.